To predict arrhythmic risk in carriers of filamin C truncating variants, a novel risk predictive model was developed based on ...

Johnson & Johnson said on Friday it resumed the limited market release of its Varipulse heart device in the United States ...

Johnson & Johnson MedTech announced that it intends to resume the rollout of its Varipulse platform in the U.S. after a ...

J&J said it found no immediate procedure-related causes from the atrial fibrillation therapy but that risks can escalate if a ...

The instructions for use have been updated to address issues that led to a greater risk of neurovascular events in an early ...

Johnson & Johnson is set to resume the limited market release of the Varipulse Catheter, a treatment option for atrial ...

Johnson & Johnson (JNJ) stock in focus as limited rollout of Varipulse heart device resumes after a safety review prompted by ...

J.P. Morgan analysts said the findings of J&J’s investigation “could significantly hinder the product’s rollout in the U.S.

Johnson & Johnson (NYSE:JNJ) has decided to resume a limited market rollout of its heart rhythm device Varipulse after an investigation indicated no safety concerns, the MedTech giant announced.

Johnson & Johnson (NYSE: JNJ) announced on Friday that it is set to recommence the limited market release of its VARIPULSE™ devices in the United States. The de ...

Bengaluru: Johnson & Johnson said on Friday it resumed the limited market release of its Varipulse heart device in the United States after an investigation found the devices operate as intended.